Fig. 2: Downregulation of PPP2R2B in intrinsic resistance to HER2-targeted therapies in cellular models.
From: EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
a Representative RT-qPCR (left; n = 2) and western blot (right; n = 2) assessing the expression of the indicated PP2A members in the indicated cell lines. RT-qPCR data are expressed as mean ± s.d. of technical triplicates. b Representative images (top) and quantification (bottom) of clonogenic assay for the responses of the indicated cell lines to lapatinib. c Representative images (top) and quantification (bottom) of clonogenic assay for the responses of the indicated cell lines to trastuzumab. Data in b and c are expressed as means ± s.d. of three independent experiments. P values in b and c were determined by two-way ANOVA. d Representative western blot analysis (n = 2) of signaling pathways downstream of HER2 with the indicated cell lines treated with or without 10 µg/ml trastuzumab or 40 nM lapatinib. Effectors downstream of mTOR were highlighted in red. The cell line sensitive to HER2 inhibition (BT474) is labeled in blue, whereas the ones resistant (SKBR3 and UACC812) are in red.
